Toth Financial Advisory’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-5,680
| Closed | -$782K | – | 746 |
|
|
2024
Q2 | $782K | Buy |
5,680
+180
| +3% | +$24.8K | 0.1% | 132 |
|
|
2024
Q1 | $759K | Buy |
5,500
+1,413
| +35% | +$195K | 0.09% | 139 |
|
|
2023
Q4 | $539K | Buy |
+4,087
| New | +$539K | 0.07% | 162 |
|
|
2023
Q1 | – | Sell |
-7,185
| Closed | -$858K | – | 831 |
|
|
2022
Q4 | $858K | Buy |
+7,185
| New | +$858K | 0.14% | 113 |
|
|
2020
Q4 | – | Sell |
-490
| Closed | -$47K | – | 612 |
|
|
2020
Q3 | $47K | Sell |
490
-6,845
| -93% | -$657K | 0.01% | 245 |
|
|
2020
Q2 | $895K | Buy |
7,335
+6,130
| +509% | +$748K | 0.19% | 98 |
|
|
2020
Q1 | $104K | Sell |
1,205
-4,350
| -78% | -$375K | 0.03% | 141 |
|
|
2019
Q4 | $597K | Buy |
+5,555
| New | +$597K | 0.12% | 115 |
|